Demo
AQST Nasdaq· Aquestive Therapeutics Inc.
FundamentalsNews digest Peer analysis
Login
AQST Nasdaq· Aquestive Therapeutics Inc.
Earnings report Q3 2023

Aquestive Therapeutics Reports 13% Increase in Revenue for the Latest Quarter

Segments of revenue

Aquestive Therapeutics reported total revenues of $13.0 million for the latest quarter, representing a 13% increase compared to the same period last year. The breakdown of revenue segments is as follows:

  • Manufacture and supply revenue: $11.4 million, showing a significant increase of 36% compared to the previous year. This growth can be attributed to increased demand for Aquestive's products and services in the market.

  • License and royalty revenue: $1.1 million, a substantial increase of 193% compared to the same quarter last year. This growth can be attributed to successful licensing agreements and increased royalty payments from partners.

  • Co-development and research fees: $0.5 million, representing a 24% increase compared to the previous year. This growth can be attributed to successful collaborations and increased research activities.

  • Proprietary product sales, net: No revenue was generated from proprietary product sales in the latest quarter, compared to $2.3 million in the same period last year.

Strengths

Aquestive Therapeutics demonstrated a strong performance in terms of revenue growth in the latest quarter. The significant increase in manufacture and supply revenue indicates a growing demand for the company's products and services. The substantial increase in license and royalty revenue highlights successful partnerships and the ability to generate additional income streams. The growth in co-development and research fees reflects the company's commitment to innovation and collaboration.

Challenges

Aquestive Therapeutics faced a decline in proprietary product sales, with no revenue generated in the latest quarter. This indicates a potential challenge in the company's proprietary product portfolio and the need for strategic adjustments to improve sales performance.

Noteworthy

The overall revenue growth of 13% for the latest quarter is a positive indicator of Aquestive Therapeutics' financial performance. The company's focus on manufacturing and supply, as well as successful licensing agreements, has contributed to this growth. However, the decline in proprietary product sales is worth noting and may require further analysis to identify the underlying factors.

Summary

Aquestive Therapeutics reported a 13% increase in revenue for the latest quarter, driven by strong performance in manufacture and supply revenue, license and royalty revenue, and co-development and research fees. The company's ability to meet growing demand and establish successful partnerships has contributed to its revenue growth. However, the decline in proprietary product sales presents a challenge that requires attention. Overall, Aquestive Therapeutics' financial performance in terms of revenue demonstrates positive momentum, but further analysis is needed to address the decline in proprietary product sales.

Source documents

Form 10-Q  filed on Nov 06, 2023
22 pages scanned

Reference data

Company financials Q3 revenue 13.2M
Analyst estimates Q3 EPS missed by -16.64%
Sign up to Fey

Get in-depth analysis on thousands of stocks for just $30/month. Cancel anytime.